학술논문
Have You Heard the News? Artemether-lumefantrine is Now Recommended for ALL Uncomplicated Malaria in the United States, Including in Pregnancy.
Document Type
Academic Journal
Author
Castro L; Malaria Branch, Division of Parasitic Diseases and Malaria, Global Health Center, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Epidemic Intelligence Service, Center for Surveillance, Epidemiology and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Ridpath A; Malaria Branch, Division of Parasitic Diseases and Malaria, Global Health Center, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Mace K; Malaria Branch, Division of Parasitic Diseases and Malaria, Global Health Center, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Gutman JR; Malaria Branch, Division of Parasitic Diseases and Malaria, Global Health Center, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Source
Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE
Subject
Language
English
Abstract
Competing Interests: Potential conflicts of interest . A. R. reports individual stocks unrelated to this manusript from Johnson and Johnson, Abbvie Inc, Git Lab Inc., Phillips 66, BioNTech SE-ADR, Amgen Inc, Protagonist Therapeutics, Immunic Inc, Infinity Pharmaceuticals Inc., and Pfizer Inc. J. R. G. reports participation on a number of trial data and safety monitoring boards (DSMBs), including the Pyrapreg and Cardio safety of dihydroartemisinin-piperaquine among pregnant women in Tanzania (no reimbursement or honoraria received for this work); a role as co-chair of the Roll Back Malaria Malaria in Pregnancy working group. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.